慢性阻塞性肺病6型™ 确定在症状前阶段有COPD风险的患者，以便进行早期医疗干预并促进更好的临床结果。这项开创性的设备筛选出那些FEV1正常的人，因此，没有COPD假阴性风险的人，使肺功能测定资源集中在那些最有风险的人身上。
| 参数显示 | 预测的FEV1/FEV6/比率和百分比 |
| 吹风指标质量: | 是的 |
| 阻塞性指数: | 轻度、中度、重度(预测FEV1%) |
| 慢性阻塞性肺病的分类: | 正常(COPD);第一、二、三、四阶段(预计FEV1%) |
| 肺年龄指标: | 是的 |
| 流阻抗: | 14l /s时优于0.15 kPa/L/s |
| 传感器: | 定子转子 |
| 工作温度范围: | 17 - 37°c(62.6 - 98.6°f) |
| 准确性: | 优于±3% |
| 范围： | 0 - 9.99 l BTPS |
| 大小: | 113 x 63 x 48毫米 |
| 重量: | 55 g网 |
| 显示: | 自定义液晶显示 |
| 力量: | AAA电池 |
| 性能标准： | Iso 26782:2009, Iso 23747:2007, ats / ers 2005 |
| 安全标准： | IEC 60601 - 1:2005 |
| 医疗安全标准: | 医疗装置93/42/EEC(经修正) |
| 按照QA/GMP标准设计和制造: | ISO 13485:2003 FDA 21CFR820标准 |
Protect your patient and your testing instruments with the VBMax™ Pulmonary Function Filter. VBMax™ provides a high degree of protection for the patient as well as your testing equipment, while its low resistance allows for accurate testing results.
Independent laboratory tests have verified that this pulmonary function filter is highly effective. VBMax™ consistently filters out more than 99.999% of bacteria and 99.99% of viruses. At the same time, VBMax™ easily surpasses published ATS recommendations for flow resistance in pulmonary function instrumentation, which suggest resistance should be below 1.5 cm H2O/L/sec at flow rates of 14 L/sec.
